{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:58:22Z","timestamp":1788141502067,"version":"build-2803163510"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11154-021-09677-7","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T10:03:27Z","timestamp":1626948207000},"page":"1157-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-8695","authenticated-orcid":false,"given":"John G.","family":"Rizk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Jose G.","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gabardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elani","family":"Streja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"issue":"4","key":"9677_CR1","first-page":"1013","volume":"56","author":"JW Jones","year":"1993","unstructured":"Jones JW, Gruessner RW, Gores PF, Matas AJ. Hypoaldosteronemic hyporeninemic hyperkalemia after renal transplantation. Transplantation. 1993;56(4):1013\u20135.","journal-title":"Transplantation"},{"key":"9677_CR2","doi-asserted-by":"publisher","unstructured":"ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-threatening electrolyte abnormalities. Circulation. 2005;112(24 Suppl):IV121\u2013125. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.166563","DOI":"10.1161\/CIRCULATIONAHA.105.166563"},{"issue":"1","key":"9677_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","volume":"97","author":"CM Clase","year":"2020","unstructured":"Clase CM, Carrero JJ, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, Kovesdy CP, Kline GA, Lindner G, Obrador GT, Palmer BF, Cheung M, Wheeler DC, Winkelmayer WC, Pecoits-Filho R. Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42\u201361.","journal-title":"Kidney Int"},{"issue":"12","key":"9677_CR4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156\u201362.","journal-title":"Arch Intern Med"},{"issue":"17","key":"9677_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","volume":"39","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, Hasegawa T, Heerspink HL, Hirayama A, Landman GWD, Levin A, Nitsch D, Wheeler DC, Coresh J, Hallan SI, Shalev V, Grams ME. CKD Prognosis Consortium Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39(17):1535\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehy100.","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"9677_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ajt.16502","volume":"21","author":"A Hart","year":"2021","unstructured":"Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, Robinson A, Foutz J, Booker SE, Israni AK, Hirose R, Snyder JJ. OPTN\/SRTR 2019 Annual Data Report: Kidney. Am J Transplant. 2021;21(Suppl 2):21\u2013137.","journal-title":"Am J Transplant"},{"issue":"11","key":"9677_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrneph.2014.168","volume":"10","author":"CP Kovesdy","year":"2014","unstructured":"Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10(11):653\u201362.","journal-title":"Nat Rev Nephrol"},{"key":"9677_CR8","doi-asserted-by":"crossref","unstructured":"Bridgeman MB, Shah M, Foote E. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy. Nephrol Dial Transplant. 2019;34(Suppl 3):iii45-iii50.","DOI":"10.1093\/ndt\/gfz223"},{"issue":"1","key":"9677_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/MNH.0000000000000657","volume":"30","author":"J Rizk","year":"2021","unstructured":"Rizk J, Quan D, Gabardi S, Rizk Y, Kalantar-Zadeh K. Novel approaches to management of hyperkalaemia in kidney transplantation. Curr Opin Nephrol Hypertens. 2021;30(1):27\u201337. https:\/\/doi.org\/10.1097\/MNH.0000000000000657.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"9677_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa1506027","volume":"374","author":"F Vincenti","year":"2016","unstructured":"Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016;374(4):333\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"9677_CR11","doi-asserted-by":"publisher","first-page":"F817","DOI":"10.1152\/ajprenal.1998.274.5.F817","volume":"274","author":"G Giebisch","year":"1998","unstructured":"Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol. 1998;274(5):F817\u201333. https:\/\/doi.org\/10.1152\/ajprenal.1998.274.5.F817.","journal-title":"Am J Physiol"},{"issue":"6","key":"9677_CR12","doi-asserted-by":"publisher","first-page":"F1109","DOI":"10.1152\/ajprenal.1998.274.6.F1109","volume":"274","author":"RW Wilson","year":"1998","unstructured":"Wilson RW, Wareing M, Kibble J, Green R. Potassium permeability in the absence of fluid reabsorption in proximal tubule of the anesthetized rat. Am J Physiol. 1998;274(6):F1109\u201312. https:\/\/doi.org\/10.1152\/ajprenal.1998.274.6.F1109.","journal-title":"Am J Physiol"},{"issue":"3 Pt 2","key":"9677_CR13","doi-asserted-by":"publisher","first-page":"F387","DOI":"10.1152\/ajprenal.1987.252.3.F387","volume":"252","author":"K Tabei","year":"1987","unstructured":"Tabei K, Imai MK. Transport in upper portion of descending limbs of long-loop nephron from hamster. Am J Physiol. 1987;252(3 Pt 2):F387\u201392. https:\/\/doi.org\/10.1152\/ajprenal.1987.252.3.F387.","journal-title":"Am J Physiol"},{"issue":"3","key":"9677_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1172\/JCI115962","volume":"90","author":"F Leviel","year":"1992","unstructured":"Leviel F, Borensztein P, Houillier P, Paillard M, Bichara M. Electroneutral K+\/HCO3- cotransport in cells of medullary thick ascending limb of rat kidney. J Clin Invest. 1992;90(3):869\u201378. https:\/\/doi.org\/10.1172\/JCI115962.","journal-title":"J Clin Invest"},{"issue":"5","key":"9677_CR15","doi-asserted-by":"publisher","first-page":"F1030","DOI":"10.1152\/ajprenal.00169.2004","volume":"287","author":"G Frindt","year":"2004","unstructured":"Frindt G, Palmer LG. Apical potassium channels in the rat connecting tubule. Am J Physiol Renal Physiol. 2004;287(5):F1030\u20137. https:\/\/doi.org\/10.1152\/ajprenal.00169.2004.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"9677_CR16","doi-asserted-by":"publisher","first-page":"F517","DOI":"10.1152\/ajprenal.00118.2006","volume":"291","author":"JL Pluznick","year":"2006","unstructured":"Pluznick JL, Sansom SC. BK channels in the kidney: role in K(+) secretion and localization of molecular components. Am J Physiol Renal Physiol. 2006;291(3):F517\u201329. https:\/\/doi.org\/10.1152\/ajprenal.00118.2006.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"9677_CR17","doi-asserted-by":"publisher","first-page":"F153","DOI":"10.1152\/ajprenal.2000.279.1.F153","volume":"279","author":"X Zhou","year":"2000","unstructured":"Zhou X, Lynch IJ, Xia SL, Wingo CS. Activation of H(+)-K(+)-ATPase by CO(2) requires a basolateral Ba(2+)-sensitive pathway during K restriction. Am J Physiol Renal Physiol. 2000;279(1):F153\u201360. https:\/\/doi.org\/10.1152\/ajprenal.2000.279.1.F153.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"9677_CR18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1046\/j.1523-1755.2000.00970.x","volume":"57","author":"LG Palmer","year":"2000","unstructured":"Palmer LG, Frindt G. Aldosterone and potassium secretion by the cortical collecting duct. Kidney Int. 2000;57(4):1324\u20138. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00970.x.","journal-title":"Kidney Int"},{"key":"9677_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199610270-00025","author":"B Kaplan","year":"1996","unstructured":"Kaplan B, Wang Z, Abecassis MM, Fryer JP, Stuart FP, Kaufman DB. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation. 1996. https:\/\/doi.org\/10.1097\/00007890-199610270-00025.","journal-title":"Transplantation"},{"key":"9677_CR20","doi-asserted-by":"publisher","unstructured":"Kim HC, Hwang EA, Han SY, Park SB, Kim HT, Cho WH. Primary immunosuppression with tacrolimus in kidney transplantation: Three-year follow-up in a single center. In: Transplantation Proceedings. 2004. https:\/\/doi.org\/10.1016\/j.transproceed.2004.08.006","DOI":"10.1016\/j.transproceed.2004.08.006"},{"key":"9677_CR21","doi-asserted-by":"publisher","DOI":"10.21542\/gcsp.2018.5","author":"JK McDermott","year":"2018","unstructured":"McDermott JK, Girgis RE. Individualizing immunosuppression in lung transplantation. Glob Cardiol Sci Pract. 2018. https:\/\/doi.org\/10.21542\/gcsp.2018.5.","journal-title":"Glob Cardiol Sci Pract"},{"key":"9677_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2497","author":"EJ Hoorn","year":"2011","unstructured":"Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011. https:\/\/doi.org\/10.1038\/nm.2497.","journal-title":"Nat Med"},{"key":"9677_CR23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-0012.2003.00154.x","author":"PJ Heering","year":"2004","unstructured":"Heering PJ, Kurschat C, Vo DT, Klein-Vehne N, Fehsel K, Ivens K. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. Clin Transplant. 2004. https:\/\/doi.org\/10.1046\/j.1399-0012.2003.00154.x.","journal-title":"Clin Transplant"},{"key":"9677_CR24","doi-asserted-by":"publisher","DOI":"10.1210\/endo.143.5.8821","author":"CE Deppe","year":"2002","unstructured":"Deppe CE, Heering PJ, Viengchareun SAY, Grabensee B, Farman N, Lombes M. Cyclosporine A and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: A cell-based model to investigate partial aldosterone resistance in kidney transplantation. Endocrinology. 2002. https:\/\/doi.org\/10.1210\/endo.143.5.8821.","journal-title":"Endocrinology"},{"key":"9677_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)70324-4","author":"Y Pei","year":"1993","unstructured":"Pei Y, Richardson R, Greenwood C, Wong PY, Baines A. Extrarenal Effect of Cyclosporine A on Potassium Homeostasis in Renal Transplant Recipients. Am J Kidney Dis. 1993. https:\/\/doi.org\/10.1016\/S0272-6386(12)70324-4.","journal-title":"Am J Kidney Dis"},{"key":"9677_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23440","author":"EF Martin","year":"2012","unstructured":"Martin EF, Huang J, Xiang Q, Klein JP, Bajaj J, Saeian K. Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: An analysis of the united network for organ sharing database. Liver Transplant. 2012. https:\/\/doi.org\/10.1002\/lt.23440.","journal-title":"Liver Transplant"},{"key":"9677_CR27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00008","author":"H Vel\u00e1zquez","year":"1993","unstructured":"Vel\u00e1zquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993. https:\/\/doi.org\/10.7326\/0003-4819-119-4-199308150-00008.","journal-title":"Ann Intern Med"},{"key":"9677_CR28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-2-199501150-00004","author":"TR Kleyman","year":"1995","unstructured":"Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: Inhibition of distal nephron sodium transport. Ann Intern Med. 1995. https:\/\/doi.org\/10.7326\/0003-4819-122-2-199501150-00004.","journal-title":"Ann Intern Med"},{"issue":"2","key":"9677_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5049\/EBP.2007.5.2.111","volume":"5","author":"YW Kim","year":"2007","unstructured":"Kim YW. Antimicrobial-induced Electrolyte and Acid-Base Disturbances. Electrolyte Blood Press. 2007;5(2):111\u20135. https:\/\/doi.org\/10.5049\/EBP.2007.5.2.111.","journal-title":"Electrolyte Blood Press"},{"key":"9677_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303113281006","author":"MJ Choi","year":"1993","unstructured":"Choi MJ, Fernandez PC, Patnaik A, et al. Trimethoprim-Induced Hyperkalemia in a Patient with AIDS. N Engl J Med. 1993. https:\/\/doi.org\/10.1056\/NEJM199303113281006.","journal-title":"N Engl J Med"},{"key":"9677_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/815907","author":"LC Nickels","year":"2012","unstructured":"Nickels LC, Jones C, Stead LG. Trimethoprim-Sulfamethoxazole-Induced Hyperkalemia in a Patient with Normal Renal Function. Case Rep Emerg Med. 2012. https:\/\/doi.org\/10.1155\/2012\/815907.","journal-title":"Case Rep Emerg Med"},{"key":"9677_CR32","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.16220","author":"M Ko\u00e7","year":"2000","unstructured":"Ko\u00e7 M, Bihorac A, Ozener CI, Kantarci G, Akoglu E. Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole. Am J Kidney Dis. 2000. https:\/\/doi.org\/10.1053\/ajkd.2000.16220.","journal-title":"Am J Kidney Dis"},{"key":"9677_CR33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.43869000.x","author":"JF Bugge","year":"1996","unstructured":"Bugge JF. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. J Intern Med. 1996. https:\/\/doi.org\/10.1046\/j.1365-2796.1996.43869000.x.","journal-title":"J Intern Med"},{"key":"9677_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80147-0","author":"M Lachaal","year":"1989","unstructured":"Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989. https:\/\/doi.org\/10.1016\/S0002-9343(89)80147-0.","journal-title":"Am J Med"},{"key":"9677_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02290-15","author":"N Macesic","year":"2016","unstructured":"Macesic N, Urbancic K, Ierino F, Grayson ML. Is aerosolized pentamidine for pneumocystis pneumonia prophylaxis in renal transplant recipients not as safe as we might think? Antimicrob Agents Chemother. 2016. https:\/\/doi.org\/10.1128\/AAC.02290-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"9677_CR36","doi-asserted-by":"publisher","DOI":"10.1378\/chest.109.5.1250","author":"K Saukkonen","year":"1996","unstructured":"Saukkonen K, Garland R, Koziel H. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Chest. 1996. https:\/\/doi.org\/10.1378\/chest.109.5.1250.","journal-title":"Chest"},{"key":"9677_CR37","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.417","author":"SD Nathan","year":"1994","unstructured":"Nathan SD, Ross DJ, Zakowski P, Kass RM, Koerner SK. Utility of inhaled pentamidine prophylaxis in lung transplant recipients. Chest. 1994. https:\/\/doi.org\/10.1378\/chest.105.2.417.","journal-title":"Chest"},{"key":"9677_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199210000-00010","author":"JL Colombo","year":"1992","unstructured":"Colombo JL, Sammut PH, Langnas AN, Shaw BW. The spectrum of Pneumocystis carinii infection after liver transplantation in children. Transplantation. 1992. https:\/\/doi.org\/10.1097\/00007890-199210000-00010.","journal-title":"Transplantation"},{"key":"9677_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102501102","author":"LL Briceland","year":"1991","unstructured":"Briceland LL, Bailie GR. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. Ann Pharmacother. 1991. https:\/\/doi.org\/10.1177\/106002809102501102.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"9677_CR40","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1128\/aac.32.10.1490","volume":"32","author":"JE Conte Jr","year":"1988","unstructured":"Conte JE Jr, Golden JA. Concentrations of aerosolized pentamidine in bronchoalveolar lavage, systemic absorption, and excretion. Antimicrob Agents Chemother. 1988;32(10):1490\u20133. https:\/\/doi.org\/10.1128\/aac.32.10.1490.","journal-title":"Antimicrob Agents Chemother"},{"key":"9677_CR41","doi-asserted-by":"publisher","DOI":"10.4103\/0971-9784.203933","author":"MK Sahu","year":"2017","unstructured":"Sahu MK, Singh SP, Das A, et al. High blood tacrolimus and hyperkalemia in a heart transplant patient. Ann Card Anaesth. 2017. https:\/\/doi.org\/10.4103\/0971-9784.203933.","journal-title":"Ann Card Anaesth"},{"key":"9677_CR42","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/12382_8","author":"JC Hollander-Rodriguez","year":"2006","unstructured":"Hollander-Rodriguez JC, Calvert JF. Hyperkalemia. Am Fam Physician. 2006. https:\/\/doi.org\/10.5005\/jp\/books\/12382_8.","journal-title":"Am Fam Physician"},{"issue":"3","key":"9677_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pcad.2020.02.002","volume":"63","author":"J Rizk","year":"2020","unstructured":"Rizk J, Mehra MR. Anticoagulation management strategies in heart transplantation. Prog Cardiovasc Dis. 2020;63(3):210\u20138. https:\/\/doi.org\/10.1016\/j.pcad.2020.02.002.","journal-title":"Prog Cardiovasc Dis"},{"key":"9677_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12119","author":"SI Martin","year":"2013","unstructured":"Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant. 2013. https:\/\/doi.org\/10.1111\/ajt.12119.","journal-title":"Am J Transplant"},{"key":"9677_CR45","doi-asserted-by":"publisher","unstructured":"Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004. https:\/\/doi.org\/10.1128\/CMR.17.4.770-782.2004","DOI":"10.1128\/CMR.17.4.770-782.2004"},{"key":"9677_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198903000-00032","author":"RM Higgins","year":"1989","unstructured":"Higgins RM, Bloom SL, Hopkin JM, Morris PJ. The risks and benefits of low-dose cotrimoxazole prophylaxis for pneumocystis pneumonia in renal transplantation. Transplantation. 1989. https:\/\/doi.org\/10.1097\/00007890-198903000-00032.","journal-title":"Transplantation"},{"key":"9677_CR47","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00007","author":"S Greenberg","year":"1993","unstructured":"Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med. 1993. https:\/\/doi.org\/10.7326\/0003-4819-119-4-199308150-00007.","journal-title":"Ann Intern Med"},{"key":"9677_CR48","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-3-199602010-00006","author":"R Alappan","year":"1996","unstructured":"Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1996. https:\/\/doi.org\/10.7326\/0003-4819-124-3-199602010-00006.","journal-title":"Ann Intern Med"},{"key":"9677_CR49","doi-asserted-by":"crossref","unstructured":"Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: Hyperkalemia is an important complication regardless of dose. Clin Nephrol. 1996.","DOI":"10.7326\/0003-4819-125-9-199611010-00024"},{"key":"9677_CR50","doi-asserted-by":"publisher","DOI":"10.7182\/pit2015153","author":"M Zmarlicka","year":"2015","unstructured":"Zmarlicka M, Martin ST, Cardwell SM, Nailor MD. Tolerability of low-dose sulfamethoxazole\/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients. Prog Transplant. 2015. https:\/\/doi.org\/10.7182\/pit2015153.","journal-title":"Prog Transplant"},{"key":"9677_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3944-0","author":"GVR Prasad","year":"2019","unstructured":"Prasad GVR, Beckley J, Mathur M, et al. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect Dis. 2019. https:\/\/doi.org\/10.1186\/s12879-019-3944-0.","journal-title":"BMC Infect Dis"},{"key":"9677_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01079.x","author":"I Lee","year":"2005","unstructured":"Lee I, Barton TD, Goral S, et al. Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant. 2005. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01079.x.","journal-title":"Am J Transplant"},{"key":"9677_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12968","author":"KF Urbancic","year":"2018","unstructured":"Urbancic KF, Pisasale D, Wight J, Trubiano JA. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients. Transpl Infect Dis. 2018. https:\/\/doi.org\/10.1111\/tid.12968.","journal-title":"Transpl Infect Dis"},{"key":"9677_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12769","author":"MM McLaughlin","year":"2017","unstructured":"McLaughlin MM, Galal A, Richardson CL, et al. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population. Transpl Infect Dis. 2017. https:\/\/doi.org\/10.1111\/tid.12769.","journal-title":"Transpl Infect Dis"},{"key":"9677_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2011.00691.x","author":"N Goto","year":"2011","unstructured":"Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis. 2011. https:\/\/doi.org\/10.1111\/j.1399-3062.2011.00691.x.","journal-title":"Transpl Infect Dis"},{"key":"9677_CR56","unstructured":"Mepron [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020500s017lbl.pdf (Accessed 5 Jun 2020)."},{"key":"9677_CR57","unstructured":"Dapsone [package insert]. , Barnstaple, EX32 8NS, UK: Accord; 2019. https:\/\/www.medicines.org.uk\/emc\/files\/pil.5768.pdf (Accessed 5 Jun 2020)."},{"key":"9677_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2009.01129.x","author":"JA Giullian","year":"2010","unstructured":"Giullian JA, Cavanaugh K, Schaefer H. Lower risk of urinary tract infection with low-dose trimethoprim\/sulfamethoxazole compared to dapsone prophylaxis in older renal transplant patients on a rapid steroid-withdrawal immunosuppression regimen. Clin Transplant. 2010. https:\/\/doi.org\/10.1111\/j.1399-0012.2009.01129.x.","journal-title":"Clin Transplant"},{"key":"9677_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500030207","author":"JS Plotkin","year":"1997","unstructured":"Plotkin JS, Buell JF, Njoku MJ, et al. Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: A two-case report and review. Liver Transplant Surg. 1997. https:\/\/doi.org\/10.1002\/lt.500030207.","journal-title":"Liver Transplant Surg"},{"key":"9677_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12161","author":"N Mitsides","year":"2014","unstructured":"Mitsides N, Green D, Middleton R, et al. Dapsone-induced methemoglobinemia in renal transplant recipients: More prevalent than previously thought. Transpl Infect Dis. 2014. https:\/\/doi.org\/10.1111\/tid.12161.","journal-title":"Transpl Infect Dis"},{"key":"9677_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit071","author":"M Bodro","year":"2013","unstructured":"Bodro M, Paterson DL. Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies? Clin Infect Dis. 2013. https:\/\/doi.org\/10.1093\/cid\/cit071.","journal-title":"Clin Infect Dis"},{"key":"9677_CR62","unstructured":"AIDSinfo. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. March 28, 2019. AIDSinfo. 2019."},{"key":"9677_CR63","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2008-740ST","author":"AH Limper","year":"2011","unstructured":"Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011. https:\/\/doi.org\/10.1164\/rccm.2008-740ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"9677_CR64","unstructured":"Prograf [package insert]. Deerfield, IL: Astellas Pharma US; 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050708s027,050709s021lbl.pdf (Accessed 10 Jul 2019)."},{"key":"9677_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199704150-00013","author":"JD Pirsch","year":"1997","unstructured":"Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997. https:\/\/doi.org\/10.1097\/00007890-199704150-00013.","journal-title":"Transplantation"},{"key":"9677_CR66","unstructured":"Rapamune Oral Solution and Tablets [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021110s058lbl.pdf Accessed 4 Jun 2019."},{"key":"9677_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02480-6","author":"BD Kahan","year":"2000","unstructured":"Kahan BD, Steinberg S, Bartlett S, et al. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. Lancet. 2000. https:\/\/doi.org\/10.1016\/S0140-6736(00)02480-6.","journal-title":"Lancet"},{"key":"9677_CR68","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200101270-00019","author":"AS MacDonald","year":"2001","unstructured":"MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001. https:\/\/doi.org\/10.1097\/00007890-200101270-00019.","journal-title":"Transplantation"},{"key":"9677_CR69","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109150-00007","author":"RWG Johnson","year":"2001","unstructured":"Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001. https:\/\/doi.org\/10.1097\/00007890-200109150-00007.","journal-title":"Transplantation"},{"key":"9677_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21827","author":"P De Simone","year":"2009","unstructured":"De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. Liver Transplant. 2009. https:\/\/doi.org\/10.1002\/lt.21827.","journal-title":"Liver Transplant"},{"key":"9677_CR71","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001524","author":"WC Chapman","year":"2017","unstructured":"Chapman WC, Brown RS, Chavin KD, et al. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in de Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. Transplantation. 2017. https:\/\/doi.org\/10.1097\/TP.0000000000001524.","journal-title":"Transplantation"},{"key":"9677_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03016.x","author":"A Durrbach","year":"2010","unstructured":"Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant. 2010. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03016.x.","journal-title":"Am J Transplant"},{"key":"9677_CR73","unstructured":"Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) (BENEFIT). Retrieved from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00256750"},{"issue":"2","key":"9677_CR74","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2215\/CJN.05840710","volume":"6","author":"L Rostaing","year":"2011","unstructured":"Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011;6(2):430\u20139. https:\/\/doi.org\/10.2215\/CJN.05840710.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"9677_CR75","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1111\/ajt.13322","volume":"15","author":"G Gupta","year":"2015","unstructured":"Gupta G, Regmi A, Kumar D, et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. Am J Transplant. 2015;15(10):2726\u201331. https:\/\/doi.org\/10.1111\/ajt.13322.","journal-title":"Am J Transplant"},{"key":"9677_CR76","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013040435","author":"MA Carpenter","year":"2014","unstructured":"Carpenter MA, John A, Weir MR, et al. BP, cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial. J Am Soc Nephrol. 2014. https:\/\/doi.org\/10.1681\/ASN.2013040435.","journal-title":"J Am Soc Nephrol"},{"key":"9677_CR77","doi-asserted-by":"publisher","DOI":"10.2174\/157340212804546062","author":"J Kaufeld","year":"2012","unstructured":"Kaufeld J, Schiffer M, Chatzikyrkou C. Pathogenesis and Management of Hypertension after Kidney Transplantation. Curr Hypertens Rev. 2012. https:\/\/doi.org\/10.2174\/157340212804546062.","journal-title":"Curr Hypertens Rev"},{"key":"9677_CR78","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2019.264","author":"G Severova-Andreevska","year":"2019","unstructured":"Severova-Andreevska G, Danilovska I, Sikole A, Popov Z, Ivanovski N. Hypertension after kidney transplantation: Clinical significance and therapeutical aspects. Open Access Maced J Med Sci. 2019. https:\/\/doi.org\/10.3889\/oamjms.2019.264.","journal-title":"Open Access Maced J Med Sci"},{"key":"9677_CR79","doi-asserted-by":"crossref","unstructured":"Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002.","DOI":"10.1681\/ASN.V1341084"},{"key":"9677_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.377","author":"BL Kasiske","year":"2010","unstructured":"Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int. 2010. https:\/\/doi.org\/10.1038\/ki.2009.377.","journal-title":"Kidney Int"},{"key":"9677_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001087","author":"G Hamdani","year":"2017","unstructured":"Hamdani G, Nehus EJ, Hanevold CD, et al. Ambulatory blood pressure, left ventricular hypertrophy, and allograft function in children and young adults after kidney transplantation. Transplantation. 2017. https:\/\/doi.org\/10.1097\/TP.0000000000001087.","journal-title":"Transplantation"},{"key":"9677_CR82","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080834","author":"MR Weir","year":"2015","unstructured":"Weir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015. https:\/\/doi.org\/10.1681\/ASN.2014080834.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"9677_CR83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40620-017-0378-x","volume":"30","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli C, Cucchiari D. Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment. J Nephrol. 2017;30(2):155\u20137. https:\/\/doi.org\/10.1007\/s40620-017-0378-x.","journal-title":"J Nephrol"},{"issue":"13","key":"9677_CR84","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s40265-020-01367-z","volume":"80","author":"JG Rizk","year":"2020","unstructured":"Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80(13):1267\u201392. https:\/\/doi.org\/10.1007\/s40265-020-01367-z.","journal-title":"Drugs"},{"key":"9677_CR85","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz092","author":"A Pisano","year":"2019","unstructured":"Pisano A, Bolignano D, Mallamaci F, et al. Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2019. https:\/\/doi.org\/10.1093\/ndt\/gfz092.","journal-title":"Nephrol Dial Transplant"},{"key":"9677_CR86","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.3.862","author":"M Hausberg","year":"1999","unstructured":"Hausberg M, Barenbrock M, Hohage H, M\u00fcller S, Heidenreich S, Rahn KH. ACE inhibitor versus \u03b2-blocker for the treatment of hypertension in renal allograft recipients. Hypertension. 1999. https:\/\/doi.org\/10.1161\/01.HYP.33.3.862.","journal-title":"Hypertension"},{"key":"9677_CR87","doi-asserted-by":"publisher","DOI":"10.1177\/0897190014566306","author":"L Hahn","year":"2015","unstructured":"Hahn L, Hahn M. Carvedilol-induced hyperkalemia in a patient with chronic kidney disease. J Pharm Pract. 2015. https:\/\/doi.org\/10.1177\/0897190014566306.","journal-title":"J Pharm Pract"},{"key":"9677_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2011.07.003","author":"MR Weir","year":"2011","unstructured":"Weir MR, Salzberg DJ. Management of hypertension in the transplant patient. J Am Soc Hypertens. 2011. https:\/\/doi.org\/10.1016\/j.jash.2011.07.003.","journal-title":"J Am Soc Hypertens"},{"key":"9677_CR89","doi-asserted-by":"publisher","DOI":"10.1159\/000065225","author":"J McCauley","year":"2002","unstructured":"McCauley J, Murray J, Jordan M, Scantlebury V, Vivas C, Shapiro R. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol. 2002. https:\/\/doi.org\/10.1159\/000065225.","journal-title":"Am J Nephrol"},{"key":"9677_CR90","unstructured":"Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol. 1990."},{"key":"9677_CR91","doi-asserted-by":"publisher","DOI":"10.1177\/0897190007300728","author":"J Hawboldt","year":"2006","unstructured":"Hawboldt J, McGrath D. Possible metoprolol-induced hyperkalemia. J Pharm Pract. 2006. https:\/\/doi.org\/10.1177\/0897190007300728.","journal-title":"J Pharm Pract"},{"key":"9677_CR92","doi-asserted-by":"publisher","unstructured":"Tantisattamo E, Molnar MZ, Ho BT, et al. Approach and Management of Hypertension After Kidney Transplantation.\u00a0Front Med (Lausanne). 2020;7:229. Published 2020 Jun 16. https:\/\/doi.org\/10.3389\/fmed.2020.00229","DOI":"10.3389\/fmed.2020.00229"},{"key":"9677_CR93","doi-asserted-by":"publisher","DOI":"10.1159\/000355135","author":"DJ Taber","year":"2013","unstructured":"Taber DJ, Srinivas TM, Pilch NA, et al. Are thiazide diuretics safe and effective antihypertensive therapy in kidney transplant recipients? Am J Nephrol. 2013. https:\/\/doi.org\/10.1159\/000355135.","journal-title":"Am J Nephrol"},{"key":"9677_CR94","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.017","author":"AD Moes","year":"2017","unstructured":"Moes AD, Hesselink DA, van den Meiracker AH, Zietse R, Hoorn EJ. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. Am J Kidney Dis. 2017. https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.017.","journal-title":"Am J Kidney Dis"},{"key":"9677_CR95","doi-asserted-by":"publisher","unstructured":"Hultin S, M. Hawley C, W. Johnson D, S. Francis R. Perioperative Care for Kidney Transplant Recipients. In: Perioperative Care for Organ Transplant Recipient.\u00a02019. https:\/\/doi.org\/10.5772\/intechopen.84388","DOI":"10.5772\/intechopen.84388"},{"issue":"1","key":"9677_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000511404","volume":"145","author":"BCS de Vries","year":"2021","unstructured":"de Vries BCS, Berger SP, Bakker SJL, de Borst MH, de Jong MFC. Pre-Transplant Plasma Potassium as a Potential Risk Factor for the Need of Early Hyperkalaemia Treatment after Kidney Transplantation: A Cohort Study. Nephron. 2021;145(1):63\u201370.","journal-title":"Nephron"},{"issue":"2 Pt 1","key":"9677_CR97","first-page":"E174","volume":"246","author":"A Alvestrand","year":"1984","unstructured":"Alvestrand A, Wahren J, Smith D, DeFronzo RA. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol. 1984;246(2 Pt 1):E174\u201380.","journal-title":"Am J Physiol"},{"issue":"1","key":"9677_CR98","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1113\/jphysiol.1970.sp009056","volume":"207","author":"GW Beeler Jr","year":"1970","unstructured":"Beeler GW Jr, Reuter H. Membrane calcium current in ventricular myocardial fibres. J Physiol. 1970;207(1):191\u2013209.","journal-title":"J Physiol"},{"issue":"1","key":"9677_CR99","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/emj.19.1.92-a","volume":"19","author":"M Davey","year":"2002","unstructured":"Davey M, Caldicott D. Calcium salts in management of hyperkalaemia. Emerg Med J. 2002;19(1):92\u20133.","journal-title":"Emerg Med J"},{"issue":"5","key":"9677_CR100","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/ki.1990.284","volume":"38","author":"M Allon","year":"1990","unstructured":"Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38(5):869\u201372.","journal-title":"Kidney Int"},{"issue":"4","key":"9677_CR101","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0272-6386(96)90460-6","volume":"28","author":"M Allon","year":"1996","unstructured":"Allon M, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis. 1996;28(4):508\u201314.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"9677_CR102","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0002-9343(88)80086-X","volume":"85","author":"A Blumberg","year":"1988","unstructured":"Blumberg A, Weidmann P, Shaw S, Gn\u00e4dinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85(4):507\u201312.","journal-title":"Am J Med"},{"issue":"5","key":"9677_CR103","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000166827","volume":"4","author":"A Sebastian","year":"1984","unstructured":"Sebastian A, Schambelan M, Sutton JM. Amelioration of hyperchloremic acidosis with furosemide therapy in patients with chronic renal insufficiency and type 4 renal tubular acidosis. Am J Nephrol. 1984;4(5):287\u2013300.","journal-title":"Am J Nephrol"},{"key":"9677_CR104","first-page":"S33","volume":"59","author":"WN Suki","year":"1997","unstructured":"Suki WN. Use of diuretics in chronic renal failure. Kidney Int Suppl. 1997;59:S33\u20135.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"9677_CR105","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1159\/000064116","volume":"92","author":"R Furuya","year":"2002","unstructured":"Furuya R, Kumagai H, Sakao T, Maruyama Y, Hishida A. Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis. Nephron. 2002;92(3):576\u201381.","journal-title":"Nephron"},{"key":"9677_CR106","doi-asserted-by":"crossref","unstructured":"Marfo K, Glicklich D. Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia. Case Rep Transplant. 2012;2012:586859.","DOI":"10.1155\/2012\/586859"},{"issue":"5","key":"9677_CR107","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1053\/j.ajkd.2006.01.014","volume":"47","author":"MO Kaisar","year":"2006","unstructured":"Kaisar MO, Wiggins KJ, Sturtevant JM, et al. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. Am J Kidney Dis. 2006;47(5):809\u201314. https:\/\/doi.org\/10.1053\/j.ajkd.2006.01.014.","journal-title":"Am J Kidney Dis"},{"issue":"264","key":"9677_CR108","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM196101192640303","volume":"19","author":"L Scherr","year":"1961","unstructured":"Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;19(264):115\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"9677_CR109","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/SMJ.0b013e31819e8978","volume":"102","author":"CE McGowan","year":"2009","unstructured":"McGowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 2009;102(5):493\u20137.","journal-title":"South Med J"},{"issue":"1","key":"9677_CR110","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00000478-199701000-00007","volume":"21","author":"A Rashid","year":"1997","unstructured":"Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol. 1997;21(1):60\u20139.","journal-title":"Am J Surg Pathol"},{"key":"9677_CR111","unstructured":"Veltassa (patiromer for oral suspension) prescribing information. Redwood City, CA: Relypsa Inc.; 2020. https:\/\/www.veltassa.com\/pi.pdf (17 Mar 2021, date last accessed)"},{"key":"9677_CR112","unstructured":"Lokelma (sodium zirconium cyclosilicate for oral suspension) prescribing information. Wilmington, DE: AstraZeneca; 2020. https:\/\/www.azpicentral.com\/lokelma.pdf (17 Mar 2021, date last accessed)"},{"issue":"9","key":"9677_CR113","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1097\/TXD.0000000000001037","volume":"6","author":"K Schnelle","year":"2020","unstructured":"Schnelle K, Winters H, Pesavento T, Singh P. Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant. Transplant Direct. 2020;6(9):e595.","journal-title":"Transplant Direct."},{"issue":"3","key":"9677_CR114","doi-asserted-by":"publisher","first-page":"e13791","DOI":"10.1111\/ctr.13791","volume":"34","author":"RJ Winstead","year":"2020","unstructured":"Winstead RJ, Demehin M, Yakubu I, Song C, Brown A, Levy M, Gupta G. Sodium zirconium cyclosilicate use in solid organ transplant recipients and its effect on potassium and immunosuppression. Clin Transplant. 2020;34(3):e13791.","journal-title":"Clin Transplant"},{"issue":"9","key":"9677_CR115","doi-asserted-by":"publisher","first-page":"e13587","DOI":"10.1111\/ctr.13587","volume":"33","author":"JA Fishman","year":"2019","unstructured":"Fishman JA, Gans H. AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13587.","journal-title":"Clin Transplant"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-021-09677-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T09:25:08Z","timestamp":1641201908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-021-09677-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9677"],"URL":"https:\/\/doi.org\/10.1007\/s11154-021-09677-7","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"16 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JGR, JGL, DQ, SG, YR, ES report they have no conflicts of interest to disclose relative to this research. CPK is a consultant for Akebia, Ardelyx, Astra-Zeneca, Bayer, Cara Therapeutics, Reata, Tricida. KKZ has received honoraria and\/or support from Abbott, Abbvie, ACI Clinical (Cara Therapeutics), Akebia, Alexion, Amgen, Ardelyx, American Society of Nephrology (ASN), Astra-Zeneca, Aveo, BBraun, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hofstra Medical School, International Federation of Kidney Foundations (IFKF), International Society of Hemodialysis (ISH), International Society of Renal Nutrition and Metabolism (ISRNM), Japanese Society of Dialysis Therapy (JSDT), Hospira, Kabi, Keryx, Kissei, Novartis, OPKO, National Institutes of Health (NIH), National Kidney Foundation (NKF), Pfizer, Regulus, Relypsa, Resverlogix, Dr Schaer, Sandoz, Sanofi, Shire, Veterans\u2019 Affairs (VA), Vifor, UpToDate, and ZS-Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}